Objective: To analyze the anti-infective treatment process and pharmaceutical care key points of one patient with pulmonary infection complicated with intracranial infection, and provide reference for rational use and medication safety of clinical antibacterial drugs. Methods and Results: The patient with lung cancer was treated at a local hospital due to fever (39℃) and headache. Based on the procalcitonin level and lung CT examination results, it was initially considered as pulmonary infection, so azithromycin+piperacillin-tazobactam sodium were administrated. However, on the next day, there were symptoms such as unconsciousness and not waking up, so the patient was admitted to Department of Neurology of our hospital for further treatment. Based on the clinical combination of fever, confusion, neck resistance and other symptoms of the patient, as well as the hemogram and cerebrospinal fluid examination results, it was determined that the patient still had intracranial infection, so vancomycin+meropenem were empirically administrated. After 3 days, the patient's infection symptoms and related indicators were significantly improved, and the cerebrospinal fluid metagenomic next-generation sequencing indicated Streptococcus pneumoniae. Clinically considering that meropenem had a strong antibacterial effect on Streptococcus pneumoniae, vancomycin was discontinued. After 6 days, intracranial infection recurred in the patient. Considering that Streptococcus pneumoniae was resistant to meropenem, vancomycin was added. Later, the infection was controlled, but the patient developed severe tinnitus and hearing loss, which might be related to vancomycin in clinical consideration, so vancomycin was discontinued again and linezolid was used instead, and symptomatic treatment was given. However, after 1 week of treatment, the intracranial infection worsened, so the treatment regimen was adjusted to moxifloxacin+ceftriaxone. After that, the patient's infection symptoms and related indicators were gradually improved, and the discharge follow-up showed that the hearing was also partially recovered. Conclusion: Intracranial infection is a relatively complex and serious infection. In the clinical anti-infective treatment regimen, the antibacterial spectrum of antibacterial drugs and the passage of the blood-brain barrier should be fully considered, and the pharmaceutical care and disposal of adverse drug reactions should be prepared to ensure the treatment effect and medication safety of patients.
Key words
intracranial infection /
pulmonary infection /
pharmaceutical care /
Streptococcus pneumoniae /
vancomycin /
hearing impairment /
adverse drug reaction
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 贾建平,陈生弟.神经病学[M].8 版.北京:人民卫生出版社,2018.
[2] Sexton DJ .成人细菌性脑膜炎的神经系统并发症[EB/OL].王翠兰,译.(2024-09-23)[2024-11-03].https://www.uptodate.cn/contents/zh-Hans/neurologic-complications-of-bacterial-meningitis-in-adults?search=%E6%88%90%E4%BA%BA%E7%BB%86%E8%8F%8C%E6%80%A7%E8%84%91%E8%86%9C%E7%82%8E%E7%9A%84%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F%E5%B9%B6%E5%8F%91%E7%97%87&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1.
[3] 黄李丹,杨美娟,孙爱华,等.肺炎链球菌耐药分子机制的研究进展[J].中南医学科学杂志,2021,49(3):275-280.
[4] 邓林强,陈益国,陈会,等.2012—2021 年江西某三甲医院临床分离肺炎链球菌的分布及耐药率变化[J].中国感染与化疗杂志,2023,23(4):480-485.
[5] Musher D M .肺炎链球菌对 β-内酰胺类抗生素的耐药性[EB/OL].吴超,译.UpToDate 临床顾问(2024-10-16)[2024-11-03].https://www.uptodate.cn/contents/zh-Hans/resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics?search=%E8%82%BA%E7%82%8E%E9%93%BE%E7%90%83%E8%8F%8C%E5%AF%B9%CE%B2-%E5%86%85%E9%85%B0%E8%83%BA%E7%B1%BB%E6%8A%97%E7%94%9F%E7%B4%A0%E7%9A%84%E8%80%90%E8%8D%AF%E6%80%A7&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1.
[6] 李斌,张哲成,王彦.神经内科住院患者感染肺炎链球菌耐药基因分析[J].中国病原生物学杂志,2019,11(6):558-561.
[7] Steyger PS.Mechanisms of ototoxicity and otoprotection[J]. Otolaryngol Clin North Am, 2021, 54(6): 1101-1115.
[8] 郭燕,胡付品,朱德妹,等.2023 年 CHINET 中国细菌耐药监测[J].中国感染与化疗杂志,2024,24(6):627-637.
[9] Hasbun RH.成人特定病原体所致细菌性脑膜炎的治疗[EB/OL].辛世萌,译.UpToDate 临床顾问(2024-05-31)[2024-11-03].https://www.uptodate.cn/contents/zh-Hans/treatment-of-bacterial-meningitis-caused-by-specific-pathogens-in-adults?search=%E6%88%90%E4%BA%BA%E7%89%B9%E5%AE%9A%E7%97%85%E5%8E%9F%E4%BD%93%E6%89%80%E8%87%B4%E7%BB%86%E8%8F%8C%E6%80%A7%E8%84%91%E8%86%9C%E7%82%8E%E7%9A%84%E6%B2%BB%E7%96%97&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1.
[10] 国家卫生健康委员会合理用药专家委员会.国家抗微生物治疗指南[M].3 版.北京:人民卫生出版社,2023.
[11] 中国医师协会神经外科医师分会神经重症专家委员会,北京医学会神经外科学分会神经外科危重症学组.神经外科中枢神经系统感染诊治中国专家共识(2021 版)[J].中华神经外科杂志,2021,37(1):2-15.
[12] Jensen ES, Cayé-Thomasen P, Bodilsen J, et al. Hearing Loss in Bacterial Meningitis Revisited-Evolution and Recovery[J]. Open Forum Infect Dis, 2023, 10(3): ofad056.
[13] Klein M, Abdel-Hadi C, Bühler R, et al.German guidelines on community-acquired acute bacterial meningitis in adults[J]. Neurol Res Pract, 2023, 5(1): 44.
[14] Lindeborg MM, Jung DH, Chan DK, et al.Prevention and management of hearing loss in patients receiving ototoxic medications[J]. Bull World Health Organ, 2022, 100(12): 789-796.
[15] Rybak L P, Ramkumar V, Mukherjea D.Ototoxicity of Non-aminoglycoside Antibiotics[J]. Frontiers in Neurology, 2021, 12: 652674.
[16] 余茜,李端超,钟时勋.糖皮质激素在治疗突发性耳聋中的应用[J].中华耳科学杂志,2020,18(2):394-398.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(1996 KB)
